Evidence map›Paper›PMID 32269775›Full record

ArticleMultidisciplinary respiratory medicine2020

An overview of efficacy and safety of ambroxol for the treatment of acute and chronic respiratory diseases with a special regard to children.

Ahmad Kantar, Ludger Klimek, Dorotheea Cazan, Annette Sperl, Ulrike Sent, Margarida Mesquita

Abstract read
In one paragraph

Article in Multidisciplinary respiratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Designing the First Trials for Parkinson's Prevention.Journal of Parkinson's disease · 2024
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Does Ambroxol alleviate kidney ischemia-reperfusion injury in rats?Iranian journal of basic medical sciences · 2022
    Article
  19. Pulmonary surfactant as a versatile biomaterial to fight COVID-19.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ahmad KantarPediatric Cough and Asthma Center, Istituti Ospedalieri Bergamaschi, University and Research Hospitals, Bergamo, Italy.
Ludger KlimekWiesbaden Center for Rhinology and Allergology, Wiesbaden, Germany.
Dorotheea CazanMaria Hilf Kliniken, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Aachen, Mönchengladbach, Germany.
Annette SperlWiesbaden Center for Rhinology and Allergology, Wiesbaden, Germany.
Ulrike SentMedical Advisor CHC GSA, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany.
Margarida MesquitaGlobal Medical Lead CHC, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Ambroxolchildrenmucoactiveover-the-counter drugsrespiratory diseases

Identifiers

PMID32269775
PMCPMC7137760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.